An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary) ; Fluorouracil; Panitumumab
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GSK; Novartis
- 19 Jun 2020 Status changed from active, no longer recruiting to completed.
- 20 May 2020 Planned End Date changed from 29 May 2020 to 30 Jun 2020.
- 20 May 2020 Planned primary completion date changed from 29 May 2020 to 30 Jun 2020.